Date:2/17/2010

may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or Company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, the possibility that the Maria Research Reactor may not be able to supply Mo 99 in a volume or form sufficient to meet our needs or at all, our ability to effectively introduce and market new products or keep pace with advances in technology, the reimbursement practices of a small number of large public and private insurers, cost-containment efforts of customers, purchasing groups, third-party payers and governmental organizations, intellectual property rights disputes, complex and costly regulation, including healthcare fraud and abuse regulations, manufacturing or supply chain problems or disruptions, rising commodity costs, recalls or safety alerts and negative publicity relating to Covidien or its products, product liability losses and other litigation liability, including legacy Tyco-related litigation, divestitures of some of our businesses or product lines, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, competition, risks associated with doing business outside of the United States, foreign currency exchange rates or potential environmental liabilities. These and other factors are identified and described in more detail in our filings with the SEC. We disclaim any obligation to update these forward-looking statements other than as required by law.

SOURCE Covidien

'/>"/>

SOURCE Covidien Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence
2. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2009 Financial Results Teleconference and Webcast
3. Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split
4. GenomeQuest Announces Boston Seminar: Sequence Data Management for Next Generation Sequencing
5. CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial
6. 3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results
7. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
8. Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD
9. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
10. Kinexus Announces the Launch of a New Protein Kinase Microarray
11. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors